Evidence map›Paper›PMID 40185089›Full record

ArticleStem cell reports2025

Competing dynamic gene regulatory networks involved in fibroblast reprogramming to hematopoietic progenitor cells.

Samiyah Shafiq, Kiyofumi Hamashima, Laura A Guest, Ali H Al-Anbaki, Fabio M R Amaral, Daniel H Wiseman, Valerie Kouskoff, Georges Lacaud, Yuin-Han Loh, Kiran Batta

Abstract read
In one paragraph

Article in Stem cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Samiyah ShafiqEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK; Cell Fate Engineering and Therapeutics Lab, Cell Biology and Therapies Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Republic of Singapore.
Kiyofumi HamashimaCell Fate Engineering and Therapeutics Lab, Cell Biology and Therapies Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Republic of Singapore.
Laura A GuestEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Ali H Al-AnbakiStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Fabio M R AmaralLeukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Daniel H WisemanEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Valerie KouskoffDevelopmental Haematopoiesis Group, Division of Developmental Biology and Medicine, The University of Manchester, Manchester, UK.
Georges LacaudStem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Yuin-Han LohCell Fate Engineering and Therapeutics Lab, Cell Biology and Therapies Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Republic of Singapore.
Kiran BattaEpigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address: kiran.batta@manchester.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct reprogramming of somatic cells offers a potentially safer therapeutic approach to generate patient-specific hematopoietic cells. However, this strategy is limited by stochasticity of reprogramming. Investigating the gene regulatory networks involved during reprogramming would help generate functional cells in adequate numbers. To address this, we developed an inducible system to reprogram fibroblasts to hematopoietic progenitor cells by ectopically expressing the two transcription factors SCL and LMO2. Transcriptome and epigenome analysis at different stages of reprogramming revealed uniform silencing of fibroblast genes and upregulation of the hemogenic endothelial program. Integrated analysis suggested that the transcription factors FLI1, GATA1/2, and KLF14 are direct targets of SCL/LMO2, which subsequently induce the hematopoietic program. Single-cell RNA sequencing revealed conflicting and competing fate decisions at intermediate stages of reprogramming. Inhibiting signaling pathways associated with competing neuronal fate enhanced reprogramming efficiency. In conclusion, this study identifies early/intermediate reprogramming events and associated pathways that could be targeted to improve reprogramming efficiency.

Indexed as

Cellular ReprogrammingFibroblastsGene Regulatory NetworksHematopoietic Stem CellsAdaptor Proteins, Signal TransducingAnimalsCell DifferentiationHumansLIM Domain ProteinsMiceSignal TransductionT-Cell Acute Lymphocytic Leukemia Protein 1TranscriptomeAdaptor Proteins, Signal TransducingLIM Domain ProteinsT-Cell Acute Lymphocytic Leukemia Protein 1cell therapiesdirect reprogramminghematopoietic progenitor cellshemogenic endotheliumLMO2neuronal fatereprogramming stochasticitySCL

Identifiers

PMID40185089
PMCPMC12143154

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.